Literature DB >> 15258997

Homogeneous immunophenotype and paucity of secondary genomic aberrations are distinctive features of endemic but not of sporadic Burkitt's lymphoma and diffuse large B-cell lymphoma with MYC rearrangement.

Thomas F E Barth1, Silja Müller, Michael Pawlita, Reiner Siebert, Josef U Rother, Gunhild Mechtersheimer, James Kitinya, Martin Bentz, Peter Möller.   

Abstract

The present study has compared immunohistological marker expression profiles and genomic imbalances in seven African endemic Burkitt's lymphomas (eBLs) with those in ten European B-cell lymphomas with MYC rearrangement as shown by fluorescence in situ hybridization (FISH) analysis. eBLs showed a typical histomorphology and a homogeneous immuno-profile: CD10+, CD38+, CD77+, bcl-2-, and IgM+. Epstein-Barr virus (EBV) DNA was present in all cases. On comparative genomic hybridization (CGH), only three out of six eBLs showed imbalances (median number of imbalances = 2), with gains on chromosome 17 in two eBLs. The European lymphomas were all highly proliferating, with a Ki-67 index of at least 90%, and included seven with morphology typical of sporadic Burkitt's lymphoma (sBL) and three immunoblastic diffuse large B-cell lymphomas with MYC rearrangement (MYCre+DLBCL). In contrast to eBL, the immuno-profiles of the European lymphomas were less homogeneous and inconsistent for CD10, CD38, CD77, IgM and bcl-2 expression. EBV DNA was not detected. In five of seven sBLs, CGH showed a higher number of imbalances (median = 6), with recurrent gains on chromosome 1q (3/7) and losses on 12q and 17p (2/7), whereas all three MYCre+DLBCLs had fewer imbalances (median = 4), with gains on 17q in two of three lymphomas. It is concluded that eBL has a homogeneous immunohistology and few secondary genomic aberrations, whereas MYC-rearranged and highly proliferating European B-cell lymphomas are a heterogeneous group that includes sBL and a subgroup of diffuse large B-cell lymphomas. Copyright 2004 Pathological Society of Great Britain and Ireland

Entities:  

Mesh:

Year:  2004        PMID: 15258997     DOI: 10.1002/path.1596

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

1.  C-MYC rearrangements are frequent in aggressive mature B-Cell lymphoma with atypical morphology.

Authors:  Xianfeng F Zhao; Anjum Hassan; Arie Perry; Yi Ning; Sanford A Stass; Louis P Dehner
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

2.  The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.

Authors:  Katrin S Hüttl; Annette M Staiger; Julia Richter; M Michaela Ott; Sabrina Kalmbach; Wolfram Klapper; Anne-Sophie Biesdorf; Lorenz Trümper; Andreas Rosenwald; Marita Ziepert; Heike Horn; German Ott
Journal:  Virchows Arch       Date:  2021-03-02       Impact factor: 4.064

3.  Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis.

Authors:  René Scholtysik; Markus Kreuz; Wolfram Klapper; Birgit Burkhardt; Alfred C Feller; Michael Hummel; Markus Loeffler; Maciej Rosolowski; Carsten Schwaenen; Rainer Spang; Harald Stein; Christoph Thorns; Lorenz Trümper; Inga Vater; Swen Wessendorf; Thorsten Zenz; Reiner Siebert; Ralf Küppers
Journal:  Haematologica       Date:  2010-09-07       Impact factor: 9.941

4.  miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.

Authors:  Michalina Zajdel; Grzegorz Rymkiewicz; Magdalena Chechlinska; Katarzyna Blachnio; Barbara Pienkowska-Grela; Beata Grygalewicz; Krzysztof Goryca; Maria Cieslikowska; Zbigniew Bystydzienski; Pawel Swoboda; Jan Walewski; Jan Konrad Siwicki
Journal:  Tumour Biol       Date:  2015-02-13

Review 5.  Primary sacral non-germinal center type diffuse large B-cell lymphoma with MYC translocation: a case report and a review of the literature.

Authors:  Asami Shimada; Kei-Ji Sugimoto; Mutsumi Wakabayashi; Hidenori Imai; Yasunobu Sekiguchi; Noriko Nakamura; Tomohiro Sawada; Yasunori Ota; Norio Komatsu; Masaaki Noguchi
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

6.  Identification of novel Myc target genes with a potential role in lymphomagenesis.

Authors:  Dragan Marinkovic; Tatjana Marinkovic; Eniko Kokai; Thomas Barth; Peter Möller; Thomas Wirth
Journal:  Nucleic Acids Res       Date:  2004-10-11       Impact factor: 16.971

Review 7.  Intracellular Signaling Pathways Involved in Childhood Acute Lymphoblastic Leukemia; Molecular Targets.

Authors:  Cristian Fabián Layton Tovar; Hugo Mendieta Zerón
Journal:  Indian J Hematol Blood Transfus       Date:  2015-10-20       Impact factor: 0.900

8.  An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.

Authors:  Marilu Nelson; Sherrie L Perkins; Bhavana J Dave; Peter F Coccia; Julia A Bridge; Elizabeth R Lyden; Nyla A Heerema; Mark A Lones; Lauren Harrison; Mitchell S Cairo; Warren G Sanger
Journal:  Br J Haematol       Date:  2009-11-04       Impact factor: 6.998

9.  Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma.

Authors:  Itziar Salaverria; Andreas Zettl; Silvia Beà; Elena M Hartmann; Sandeep S Dave; George W Wright; Evert-Jan Boerma; Philip M Kluin; German Ott; Wing C Chan; Dennis D Weisenburger; Armando Lopez-Guillermo; Randy D Gascoyne; Jan Delabie; Lisa M Rimsza; Rita M Braziel; Elaine S Jaffe; Louis M Staudt; Hans Konrad Müller-Hermelink; Elias Campo; Andreas Rosenwald
Journal:  Haematologica       Date:  2008-08-12       Impact factor: 9.941

10.  Differential IgM expression distinguishes two types of pediatric Burkitt lymphoma in mouse and human.

Authors:  Anthony B Eason; Sang-Hoon Sin; Carolina Lin; Blossom Damania; Steven Park; Yuri Fedoriw; Carlos E Bacchi; Dirk P Dittmer
Journal:  Oncotarget       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.